Search

Your search for "GNPX" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events

May 1, 2024

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating at two conferences during May. According to the announcement, Genprex CFO Ryan Confer will be presenting at the Sidoti Microcap Conference, which is held May 8–9, 2024. Confer’s presentation is slated to begin […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy

April 2, 2024

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex’s non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (“NSCLC”) […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering

March 25, 2024

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) and warrants […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offering

March 20, 2024

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the company and warrants to purchase up to 1,542,112 shares […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering

March 19, 2024

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio

March 13, 2024

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has received a Notice of Patent Grant from the Korean Patent Office. The patent, which is effective through 2037, covers the use of the company’s lead drug candidate, Reqorsa(R) Immunogene Therapy, in combination with anti-PD-1 and […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting

March 6, 2024

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting its research at next month’s 2024 American Association for Cancer Research Annual Meeting. The gathering is slated for April 5–10, 2024, and will be held in San Diego, California. According to the announcement, GNPX’s research […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications

February 7, 2024

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications. According to the announcement, the company is expanding through sponsored research agreements and material transfer agreements with several academic research collaborators. The programs will be focused on studying […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference

February 6, 2024

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient

February 5, 2024

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca’s Tagrisso(R) to treat patients with late-stage […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer

November 22, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”) by the US Food and Drug Administration (“FDA”) for its REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R) and Genentech Inc.’s Tecentriq(R) as maintenance therapy in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023

November 1, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing an overview of the company’s gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event

October 20, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is hosting an upcoming virtual key opinion leader (“KOL”); the event will focus on the current state of lung cancer treatments and the challenges facing patients. Titled  “Bringing Gene Therapy to the Fight Against Lung Cancer,” […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference

October 4, 2023

Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 at the Hynes Convention Center in […]

Press Releases

Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC

September 22, 2023

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation,” please […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program

September 20, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclusive license agreement related to a particular gene therapy for both type 1 and type 2 diabetes. “Specifically, the announcement involves a worldwide exclusive license to a patent application and […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations

September 15, 2023

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company recently announced that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to its lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference

September 7, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its CFO Ryan Confer will be providing an overview of the company’s pioneering gene therapies for cancer and diabetes at the upcoming H.C. Wainwright 25th Annual Global Investment Conference. Confer’s presentation is scheduled […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline

September 5, 2023

Clinical-stage cancer and diabetes gene therapy developer Genprex (NASDAQ: GNPX) continues to expand its intellectual property portfolio for the company’s diabetes gene therapy program, recently announcing that it has entered into an exclusive license agreement related to a particular gene therapy for both Type 1 and Type 2 diabetes. Specifically, the announcement involves a worldwide […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’

September 1, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial

August 30, 2023

Genprex (NASDAQ: GNPX), a clinical-stage company developing life-changing gene therapies for patients with cancer and diabetes, recently celebrated an important milestone: the award of an orphan drug designation. The company announced August 10 that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to its lead drug candidate, REQORSA(R) Immunogene […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Important Clinical Programs Forward

August 22, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its appointment of Suzanne Thornton-Jones, Ph.D. as senior vice president, regulatory affairs. Dr. Thornton-Jones will leverage her expertise to guide Genprex’s regulatory submissions and strategy for its pipeline of gene therapy drug candidates. “We […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(R) for Patients with SCLC

August 10, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to the company’s lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential

August 4, 2023

Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. FDA Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

July 28, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company on a mission to develop life-changing therapies for patients with cancer and diabetes, recently received a patent in China – Genprex China Patent No: 201780076886.X – from the China National Intellectual Property Administration. The granted patent broadly covers the use of the company’s drug candidate REQORSAI immunogene […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct Offering

July 24, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its previously announced registered direct offering. The offering was comprised of 7,425,744 shares of the company’s common stock as well as warrants to purchase up to 7,425,744 shares of common stock; the offering […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering

July 19, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its entry into definitive agreements with health care-focused institutional investors. The agreements are for the sale and issuance of 7,425,744 shares of the company’s common stock and warrants to purchase up to 7,425,744 shares […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh

July 18, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has signed an exclusive license agreement with the University of Pittsburgh. The agreement grants Genprex worldwide, exclusive rights to a patent application and related technology for a gene therapy targeting both type 1 and type 2 […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline

July 17, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

July 10, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with diabetes and cancer, recently disclosed favorable preliminary clinical data from the Phase 1 portion of its Acclaim-1 clinical trial. During the study, Genprex’s lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities. In addition, the company reported […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast

July 6, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, was featured in the latest episode of Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Rodney Varner, GNPX’s chairman, president and CEO, and Ryan Confer, […]

News Articles

Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3

July 6, 2023

Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. Food and Drug Administration (“FDA”) Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor […]

Press Releases

IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc.

July 6, 2023

LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination in Many of the Largest Markets

July 5, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the China National Intellectual Property Administration has granted Genprex China Patent No: 201780076886.X. According to the announcement, the broad patent covers the use of Genprex’s lead drug candidate, REQORSA(R) Immunogene Therapy, in combination […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives Fast Track Designation for Proprietary Immunogene Therapy

June 28, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has received Fast Track Designation (“FTD”) from the U.S. Food and Drug Administration (“FDA”) for its lead drug candidate, REQORSA(R) Immunogene Therapy; the designation applies when used in combination with Genentech Inc.’s Tecentriq(R) to treat patients […]

News Articles

Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode

June 23, 2023

Mark Berger, M.D., Chief Medical Officer of Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing gene therapies for patients with cancer and diabetes was featured in a recent Bell2Bell Podcast episode (https://ibn.fm/ZnVPJ). Dr. Berger talked about the Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of […]

News Articles

Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors

June 20, 2023

Clinical-stage gene therapy developer Genprex (NASDAQ: GNPX) is expanding the breadth of its drug candidate potential with positive results from a preclinical study that examines the anti-tumor immune response of a gene believed to play a key role in suppressing certain tumors. Genprex’s lead drug candidate, REQORSA immunogene therapy, uses Genprex’s proprietary, non-viral ONCOPREX Nanoparticle […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape

June 16, 2023

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORSA(R) Immunogene Therapy for Late-Stage Non-Small Cell Lung Cancer

June 14, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA(R) Immunogene Therapy in combination with Tagrisso(R) in late-stage non-small cell lung cancer (“NSCLC”) have been published in an abstract […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Chief Medical Officer Featured Guest on Latest Bell2Bell Release

June 8, 2023

Genprex (NASDAQ: GNPX) chief medical officer Dr. Mark Berger is spotlighted in the latest episode of the Bell2Bell podcast (https://ibn.fm/M3OqD). During the episode, hosted by IBN’s Jonathan Keim, the executive talks about the clinical-stage gene therapy company, which develops potentially life-changing therapies for patients with cancer and diabetes who have limited treatment options. Recorded live […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).